Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Hayden v. Portola Pharmaceuticals, Inc. et al
Case Number:
3:20-cv-00367
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Baker Botts
- Berman Tabacco
- Bernstein Litowitz
- Conrad Metlitzky
- DiCello Levitt
- Glancy Prongay
- Johnson & Johnson LLP
- K&L Gates
- Morrison Foerster
- Paul Weiss
- Robbins Geller
- Saxena White
Companies
- Citigroup Inc.
- Jackson Square Partners LLC
- Oppenheimer Holdings Inc.
- Portola Pharmaceuticals Inc.
- Southeastern Pennsylvania Transportation Authority
- The Goldman Sachs Group Inc.
- William Blair & Co. LLC
Sectors & Industries:
-
September 20, 2022
Portola Pharma Investors Ink $17.5M Deal Over Stock Declines
Investors in biotechnology company Portola Pharmaceuticals Inc. have asked a San Francisco federal judge to give an initial nod to a $17.5 million deal that would end claims the company failed to acknowledge its prime drug candidate, a blood coagulant, would face stiff competition from an off-label drug used for the same purpose, hurting investors when the company revealed its struggles to sell its drug.
-
July 02, 2020
Portola Says Stock Drop Was 'Reversal Of Fortune,' Not Fraud
Portola Pharmaceuticals pushed a California federal judge to toss a proposed class action accusing the company of misstating the actual market value of its blood coagulant, Andexxa, arguing there is no evidence it misled its shareholders.
-
March 17, 2020
Glancy Prongay Seeks To Represent Blood Clot Co. Investors
Glancy Prongay & Murray LLP on Monday sought to represent a proposed class of investors in a proposed securities fraud class action accusing biotechnology company Portola Pharmaceuticals Inc. of not properly explaining how changes related to its product reserves would affect its bottom line.